BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment

Invest New Drugs. 2015 Oct;33(5):1136-43. doi: 10.1007/s10637-015-0280-0. Epub 2015 Aug 20.

Abstract

We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to slow the disease progression. Subsequent administration of vemurafenib (960 mg twice a day) resulted in complete tumor response after 8 weeks of treatment. Literature data on the use of vemurafenib and dabrafenib in non-melanoma BRAF-mutated tumors are reviewed.

Keywords: BRAF; Clear cell sarcoma; Review; Vemurafenib.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Indoles / adverse effects
  • Indoles / therapeutic use*
  • Male
  • Middle Aged
  • Mutation
  • Proto-Oncogene Proteins B-raf / genetics*
  • Sarcoma, Clear Cell / drug therapy*
  • Skin Neoplasms / drug therapy*
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use*
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Indoles
  • Sulfonamides
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf